ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 703

Clinical Value of Autoantibodies for Lupus Myelitis and Its Subtypes: A Systematic Review

Hiroshi Oiwa1, Akira Kuriyama2, Tomoyasu Matsubara3 and Eiji Sugiyama4, 1Rheumatology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan, 2General Medicine, Kurashiki Central Hospital, Kurashiki, Japan, 3Neurology, Hiroshima University Hospital, Hiroshima, Japan, 4Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: anti-dsDNA, Antiphospholipid antibodies and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: We conducted a systematic review to investigate the clinical value of clinical characteristics and autoantibodies, especially lupus-specific antibodies, for lupus myelitis and its subtypes.

Methods: We searched PubMed, EMBASE, and ICHUSHI without language restrictions for case reports or series of lupus myelitis. We focused on cases reported since 1997, when the revised classification criteria for systemic lupus erythematosus were published. Associations between patient characteristics including autoantibodies and functional outcome, survival, and subtypes of myelitis (grey and white matter myelitis) were examined. We attempted to contact authors to supplement missing information for analysis.

Results: Our search identified 224 cases from 105 articles. White matter myelitis predicted favorable function (odds ratio, 15.18; 99% confidence interval, 3.09 to 151.31; p<0.0001). Anti-nuclear antibody also predicted favorable function (p=0.007). Age ≥50 years was associated with poor survival outcomes (p=0.007). Grey matter myelitis was associated with longitudinally extensive transverse myelitis (p<0.001) and anti-double-stranded DNA (p=0.003), and tended to be associated with anti-β2-glycoprotein I (p=0.011). White matter myelitis tended to be associated with optic neuritis and anti-neuromyelitis optica antibodies. Although our study might be susceptible to under-reporting of original cases and selection bias, we aimed to provide a conservative interpretation by setting the statistical significance threshold at p<0.01.

Conclusion: This systematic review confirmed that grey matter myelitis predicted poor functional outcome, and was associated with longitudinally extensive transverse myelitis and anti-double-stranded DNA antibodies. White matter myelitis was associated with favorable functional outcomes and may partially represent a complication of neuromyelitis optica.


Disclosure: H. Oiwa, None; A. Kuriyama, None; T. Matsubara, None; E. Sugiyama, None.

To cite this abstract in AMA style:

Oiwa H, Kuriyama A, Matsubara T, Sugiyama E. Clinical Value of Autoantibodies for Lupus Myelitis and Its Subtypes: A Systematic Review [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/clinical-value-of-autoantibodies-for-lupus-myelitis-and-its-subtypes-a-systematic-review/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-value-of-autoantibodies-for-lupus-myelitis-and-its-subtypes-a-systematic-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology